|
|
Blood, 15 May 2005, Vol. 105, No. 10, pp. 3824-3832.
Prepublished online as a Blood First Edition Paper on January 25, 2005; DOI 10.1182/blood-2004-10-3880.
 Previous Article | Table of Contents | Next Article 
GENE THERAPY
Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy
Peng H. Tan,
Sven C. Beutelspacher,
Shao-An Xue,
Yao-He Wang,
Peter Mitchell,
James C. McAlister,
D. Frank P. Larkin,
Myra O. McClure,
Hans J. Stauss,
Mary A. Ritter,
Giovanna Lombardi, and
Andrew J. T. George
From the Department of Immunology and the Cancer Research UK Molecular Oncology Unit, Division of Medicine, Faculty of Medicine, Imperial College London, Hammersmith Hospital; Jefferiss Research Trust Laboratories, Wright-Fleming Institute, Division of Medicine, Faculty of Medicine, Imperial College London, St Mary's Hospital; Moorfields Eye Hospital; and the Department of Molecular Genetics, Institute of Ophthalmology, University College London, London, United Kingdom.
Genetic modification of dendritic-cell (DC) function is an attractive approach to treat disease, either using mature DCs (mDCs) to immunize patients, or immature DCs (iDCs) to induce tolerance. Viral vectors are efficient at transducing DCs, and we have investigated the effect of transduction with a variety of viral vectors on the phenotype and function of DCs. Adenovirus (Ad), human immunodeficiency virus (HIV), equine anemia virus (EIAV), and Moloney murine leukemia virus (MMLV) all up-regulate costimulatory molecules and major histocompatibility complex (MHC) class II expression on DCs, as well as, in the case of Ad and lentiviral vectors, inducing production of Th1 and proinflammatory cytokines. Following transduction there is activation of double-stranded (ds) RNA-triggered pathways resulting in interferon (IFN)  / production. In addition, the function of virally infected DCs is altered; iDCs have an increased, and mDCs a decreased, ability to stimulate a mixed lymphocyte reaction (MLR). Viral transduction of mDCs results in up-regulation of the indoleamine 2,3-dioxygenase (IDO) enzyme, which down-regulates T-cell responsiveness. Inhibition of IDO restores the ability of mDCs to stimulate an MLR, indicating that IDO is responsible for the modulation of mDC function. These data have important implications for the use of viral vectors in the transduction of DCs.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
A cautionary tale
- David H. Munn
Blood 2005 105: 3761-3762.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
H. M. Rowe, L. Lopes, N. Brown, S. Efklidou, T. Smallie, S. Karrar, P. M. Kaye, and M. K. Collins
Expression of vFLIP in a Lentiviral Vaccine Vector Activates NF-{kappa}B, Matures Dendritic Cells, and Increases CD8+ T-Cell Responses
J. Virol.,
February 15, 2009;
83(4):
1555 - 1562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Perreau, F. Mennechet, N. Serratrice, J. N. Glasgow, D. T. Curiel, H. Wodrich, and E. J. Kremer
Contrasting Effects of Human, Canine, and Hybrid Adenovirus Vectors on the Phenotypical and Functional Maturation of Human Dendritic Cells: Implications for Clinical Efficacy
J. Virol.,
April 1, 2007;
81(7):
3272 - 3284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Brown, G. Sitia, A. Annoni, E. Hauben, L. S. Sergi, A. Zingale, M. G. Roncarolo, L. G. Guidotti, and L. Naldini
In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance
Blood,
April 1, 2007;
109(7):
2797 - 2805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-Y. Hou, A. J. Muller, M. D. Sharma, J. DuHadaway, T. Banerjee, M. Johnson, A. L. Mellor, G. C. Prendergast, and D. H. Munn
Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses
Cancer Res.,
January 15, 2007;
67(2):
792 - 801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pichlmair, S. S. Diebold, S. Gschmeissner, Y. Takeuchi, Y. Ikeda, M. K. Collins, and C. Reis e Sousa
Tubulovesicular Structures within Vesicular Stomatitis Virus G Protein-Pseudotyped Lentiviral Vector Preparations Carry DNA and Stimulate Antiviral Responses via Toll-Like Receptor 9
J. Virol.,
January 15, 2007;
81(2):
539 - 547.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Akbulut, Y. Tang, K. G. Akbulut, J. Maynard, L. Zhang, and A. Deisseroth
Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer.
Mol. Cancer Ther.,
August 1, 2006;
5(8):
1975 - 1985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Liu, L. Liu, B. S. Fletcher, and G. A. Visner
Novel Action of Indoleamine 2,3-Dioxygenase Attenuating Acute Lung Allograft Injury
Am. J. Respir. Crit. Care Med.,
March 1, 2006;
173(5):
566 - 572.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. Tan, S.-A. Xue, M. Manunta, S. C. Beutelspacher, H. Fazekasova, A.K.M. Shamsul Alam, M. O. McClure, and A. J.T. George
Effect of Vectors on Human Endothelial Cell Signal Transduction: Implications for Cardiovascular Gene Therapy
Arterioscler Thromb Vasc Biol,
March 1, 2006;
26(3):
462 - 467.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Antonia, N. Mirza, I. Fricke, A. Chiappori, P. Thompson, N. Williams, G. Bepler, G. Simon, W. Janssen, J.-H. Lee, et al.
Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer
Clin. Cancer Res.,
February 1, 2006;
12(3):
878 - 887.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. Tan, J. B. Yates, S.-A. Xue, C. Chan, W. J. Jordan, J. E. Harper, M. P. Watson, R. Dong, M. A. Ritter, R. I. Lechler, et al.
Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression
Blood,
November 1, 2005;
106(9):
2936 - 2943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
